Drug
GLPG-0259 clinical trials
Also written GLPG0259.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
- GLPG0259
- 3
Studies by the year they started
5 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2009 | 3 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GLPG-0259 is read from its arms, and is right about nine times in ten.
Testing it · 5
- First-in-Human Single Ascending and Multiple Dose of GLPG0259CompletedPhase 1Galapagos NVNCT00905138Written as GLPG0259
- GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy SubjectsCompletedPhase 1Galapagos NVNCT00989703Written as GLPG0259
- GLPG0259 in Methotrexate-refractory Rheumatoid ArthritisCompletedPhase 2Galapagos NVNCT01211249Written as GLPG0259 oral capsule
- Oral Bioavailability of Two Solid Formulations of GLPG0259.CompletedPhase 1Lakefront Biotherapeutics NVNCT01322451Written as GLPG0259 fumarate
- GLPG0259 Solid Formulation Bioavailability and Food EffectCompletedPhase 1Galapagos NVNCT01024517Written as GLPG0259 solution